Protocol Clinics Price Epigenetics. The SRI Tracks Bedtime.
The SRI Signal
The Charlotte Observer's coverage of large-cohort sleep research this week names the Sleep Regularity Index (SRI) -- a scalar computed from wrist-accelerometry across 30-day windows -- as the variable tracking all-cause mortality risk, independent of sleep duration. The SRI captures nightly sleep-onset variance. A patient who sleeps eight hours at variable times registers poorly. The protocol market cannot schedule an SRI improvement. There is no clinic visit for it.
The American College of Sports Medicine, which sets clinical exercise guidelines for international practice, revised its position on resistance training this week: training to momentary muscular failure is not necessary for strength or hypertrophy gains across general populations. It has been marketed as necessary for a decade. The revision does not support that claim. Two signals in one week (sleep regularity, exercise failure-threshold) point the same direction: the behaviourally consistent variable outperforms the technically precise one. A Singapore household paying for a personalised resistance-training protocol calibrated to epigenetic-age scores is buying precision on a variable the week's data does not prioritise. The ACSM revision is on the record. The Singapore clinic pricing next month's resistance protocol has not updated its threshold.
Capital's Clinical Premise
This week's celebrity protocol coverage surveys a menu: IV NAD+ infusions, peptide protocols, continuous glucose monitoring, epigenetic-age blood panels, VO2-max benchmarking programs. The coverage does not answer the question it raises. Are these interventions calibrated to all-cause mortality endpoints, or to proxy measurements that produce numbers the buyer can name?
The regulatory architecture defines the floor. MOH Singapore's Health Sciences Authority regulates clinic-administered supplements and IV preparations under the Health Products Act; the evidentiary requirement is safety and labelling compliance, not efficacy against a mortality endpoint. TGA Australia's Listed Medicines pathway -- which covers complementary and health products in clinical settings -- requires manufacturer evidence of safety and traditional use, not randomised-trial evidence of efficacy against a named endpoint. A patient in a Singapore protocol clinic purchasing an IV NAD+ course is operating in a space where the regulator has not verified the product works against the endpoint the buyer is pricing. The capital is pricing epigenetic-age precision. The regulatory architecture is pricing a safety clearance. The HSA clearance is on file. The randomised trial against a mortality endpoint is not.
MOH Singapore's National Steps Challenge has tracked daily step count since 2015. The annual health screening framework does not include a sleep-regularity benchmark. Singapore's Health Promotion Board recommends seven to nine hours of sleep for adults, not a variance target. The HPB review cycle determines whether sleep regularity enters public guidance or stays on the protocol clinic's menu. If the next cycle closes without a variance benchmark, the protocol market holds the variable and the public framework holds the duration figure. The next review date is not published.